Description

CJC + Ipamorelin is a specialized dual-peptide formulation combining a growth hormone-releasing hormone analogue with a selective growth hormone secretagogue for advanced laboratory investigations involving endocrine signaling and peptide-mediated hormonal activity. Researchers investigate this formulation for its interaction with biological pathways associated with growth hormone secretion dynamics, IGF-1 signaling mechanisms, receptor-mediated communication, and peptide-driven metabolic regulation processes. CJC functions through growth hormone-releasing hormone receptor pathways, while Ipamorelin selectively targets growth hormone secretagogue receptors associated with pulsatile hormonal signaling activity. The combined formulation is frequently utilized in laboratory studies examining coordinated endocrine communication pathways, receptor-targeted biological interactions, and sustained peptide signaling mechanisms across advanced experimental research models. Researchers also study its structural stability and combined receptor activity profile under controlled laboratory conditions. Due to its complementary endocrine signaling characteristics, the formulation has gained significant attention in advanced hormonal pathway and peptide research investigations involving coordinated biological communication systems. Each vial is supplied as research-grade lyophilized material manufactured under controlled laboratory standards with verified purity and analytical testing protocols supporting consistency, structural integrity, and reliability in scientific peptide research applications.

Molecular Formula: Composite Peptide Blend
Molecular Weight: Combined molecular weight varies by peptide composition
Storage: Store lyophilized at −20°C under sterile laboratory conditions

FOR RESEARCH USE ONLY